Ozagrel

CHEMBL11662 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

228.2 g/mol

LogP

1.6

Phase

4

A thromboxane synthase inhibitor used in Japan to treat ischemic stroke and prevent thrombosis by reducing production of thromboxane A2, a potent promoter of platelet aggregation and vasoconstriction. It helps restore blood flow and prevents further clot formation in affected blood vessels.

Moleküler Ağırlık

228,2500 g/mol

LogP

1,60

TPSA

55,10 Å²

Lipinski RO5

Geçer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1

InChI

InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+

Molecular Formula

C13H12N2O2

HBD / HBA

1 / 3

Döndürülebilir Bağlar

4

Ağır Atomlar

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A thromboxane synthase inhibitor used in Japan to treat ischemic stroke and prevent thrombosis by reducing production of thromboxane A2, a potent promoter of platelet aggregation and vasoconstriction. It helps restore blood flow and prevents further clot formation in affected blood vessels.

Yes, Ozagrel is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL11662. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5282440. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Ozagrel PillFYI'da

Yapı

Hızlı Veriler

Formül: C13H12N2O2

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.